Hypersomnia - Pipeline Insight, 2026

DelveInsight's, "Hypersomnia - Pipeline Insight, 2026" report provides comprehensive insights about 3+ companies and 4+ pipeline drugs in Hypersomnia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Hypersomnia: Understanding

Hypersomnia: Overview

Hypersomnia is a state of excessive sleepiness which can result in decreased functioning and affect performance adversely. Hypersomnolence is defined as an inability to stay awake and alert during major waking episodes, resulting in periods of irrepressible need for sleep or unintended lapses into drowsiness or sleep. Lapses into sleep without prodromal symptoms of increasing sleepiness are called sleep attacks.

Hypersomnia is characterized by persistent excessive daytime sleepiness despite prolonged sleep duration, often exceeding 11 hours, with patients still feeling unrefreshed and struggling to stay awake during the day. Individuals commonly experience difficulty waking up, often described as "sleep drunkenness," along with confusion, irritability, or even anger upon awakening. Daytime naps are frequent but typically non-restorative. Associated symptoms include low energy levels, impaired concentration and memory, and reduced alertness, which can interfere with daily functioning. Some patients may also report anxiety, restlessness, headaches, loss of appetite, and, in certain cases, hallucinations or sleep paralysis, reflecting disruption in normal sleep-wake regulation.

The exact pathophysiology of hypersomnia remains unknown, though several potential triggers and contributing factors have been identified. These include disruption of the normal balance between sleep-promoting and wake-promoting neural systems in the brain, regulated by circadian (Process C) and homeostatic (Process S) mechanisms. Reduced activity of wake-promoting pathways or increased activity of sleep-inducing systems leads to excessive sleepiness. Key neurochemical factors include deficiency of hypocretin (orexin), which impairs wakefulness and is central to narcolepsy, and increased levels of somnogenic substances such as prostaglandin D2, adenosine, and inflammatory cytokines (e.g., IL-1, TNF-a), which promote sleep. Additional mechanisms include enhanced GABA-mediated inhibitory signaling, medication-induced suppression of alertness pathways, and neuronal damage in regions regulating sleep (e.g., hypothalamus, brainstem).

The etiology of hypersomnia remains unclear, although it is thought to involve both primary central disorders and secondary causes. Primary causes include conditions like narcolepsy (due to hypocretin deficiency), idiopathic hypersomnia, and Kleine Levin syndrome. Secondary hypersomnia is more common and results from medications (e.g., sedatives), substance use, neurological disorders (head injury, neurodegeneration), systemic illnesses (endocrine, renal, hepatic), sleep disorders such as obstructive sleep apnea, psychiatric conditions like depression, and chronic sleep deprivation.

The diagnosis of hypersomnia begins with subjective assessment of sleepiness using validated questionnaires such as the Epworth Sleepiness Scale, followed by a detailed clinical evaluation including sleep history, sleep logs, and actigraphy to assess sleep wake patterns and circadian rhythm disturbances. Objective testing is essential, with the Multiple Sleep Latency Test (MSLT) being the key diagnostic tool, particularly for narcolepsy, where findings include reduced sleep latency and the presence of sleep-onset REM periods. Management of hypersomnia focuses first on treating any underlying cause and optimizing sleep quality. Non-pharmacological measures include maintaining good sleep hygiene, scheduled short daytime naps, and regular physical activity. Pharmacological treatment primarily involves stimulants and wake-promoting agents such as modafinil or amphetamines, which enhance dopaminergic activity, along with other agents like sodium oxybate and histamine modulators (e.g., pitolisant).

"Hypersomnia - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypersomnia pipeline landscape is provided which includes the disease overview and Hypersomnia treatment guidelines. The assessment part of the report embraces, in depth Hypersomnia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypersomnia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypersomnia R&D. The therapies under development are focused on novel approaches to treat/improve Hypersomnia.

Hypersomnia Emerging Drugs Chapters

This segment of the Hypersomnia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypersomnia Emerging Drugs

• TAK-360: Takeda

TAK-360 is an oral, highly selective Orexin Receptor 2 (OX2R) agonist being developed by Takeda for Treating Idiopathic Hypersomnia (IH) and Narcolepsy Type 2. By mimicking endogenous orexin, it strengthens orexin signaling to improve wakefulness, addressing underlying sleep disorders. Its targeted mechanism offers the potential for sustained efficacy with reduced off-target effects compared to less selective wake-promoting agents. This approach may also translate into improved daytime functioning and quality of life for patients with chronic sleep wake instability. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Hypersomnia.

Hypersomnia: Therapeutic Assessment

This segment of the report provides insights about the different Hypersomnia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hypersomnia
• There are approx. 3+ key companies which are developing the therapies for Hypersomnia. The companies which have their Hypersomnia drug candidates in the mid stage, i.e. phase II include, Takeda.
• Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hypersomnia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypersomnia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypersomnia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypersomnia drugs.

Hypersomnia Report Insights

• Hypersomnia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypersomnia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypersomnia drugs?
• How many Hypersomnia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypersomnia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypersomnia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypersomnia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Centessa Pharmaceuticals
• Alkermes, Inc.

Key Products

• TAK-360
• Cleminorexton
• Alixorexton